Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of ... About eRapa eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus.

Boston area drug delivery firm Integral BioSystems LLC will present key research data May 4-7, 2025 at the Salt Palace Convention Center, ...

MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED ...

eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role ...

LLC (“Precision”) as the clinical research organization (“CRO”) to conduct the European component of the upcoming registrational Phase 3 study of eRapa in FAP. The U.S. component of the ...